50 results on '"Flowers, Christopher R."'
Search Results
2. Impact of multi-agent systemic therapy on all-cause and disease-specific survival for people living with HIV who are diagnosed with non-Hodgkin lymphoma: population-based analyses from the state of Georgia
3. Phase 1/2 study of intratumoral G100 (TLR4 agonist) with or without pembrolizumab in follicular lymphoma
4. A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma
5. Body mass index and survival of patients with lymphoma
6. Perceptions of clinical care and research among African-American patients with lymphoma
7. The impact of cell-of-origin, MYC/Bcl-2 dual expression and MYC rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy
8. Outcomes of patients with up to 6 years of follow-up from a phase 2 study of idelalisib for relapsed indolent lymphomas
9. Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria
10. How should clinicians interpret conflicting cost-effectiveness analyses for the treatment of lymphoma across nations and payer models?
11. Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma
12. SARS-CoV-2 in multiple myeloma: initial observation and management
13. Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL
14. Biologic, clinical, and sociodemographic predictors of multi-agent systemic therapy for non-Hodgkin lymphoma in people living with HIV: a population-based investigation in the state of Georgia
15. Cost burden of diffuse large B-cell lymphoma
16. Remaining challenges in predicting patient outcomes for diffuse large B-cell lymphoma
17. Insurance status impacts overall survival in Burkitt lymphoma
18. Maximizing the effectiveness of oral therapies in lymphoid cancers: research gaps and unmet needs
19. Clinical impact of Internet-based tools to guide therapeutic decisions for mantle cell lymphoma
20. PET-derived tumor metrics predict DLBCL response and progression-free survival
21. Rural and urban patients with diffuse large B-cell and follicular lymphoma experience reduced overall survival: a National Cancer DataBase study
22. Efficacy of salvage chemotherapy in diffuse large B cell lymphoma with primary treatment failure according to putative cell of origin
23. Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study
24. Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma
25. Targeting the B cell receptor pathway in non-Hodgkin lymphoma
26. Balancing patient value and payer cost in hematologic malignancies: can it be done?
27. Reasons for initiation of treatment and predictors of response for patients with Rai stage 0/1 chronic lymphocytic leukemia (CLL) receiving first-line therapy: an analysis of the Connect®CLL cohort study
28. Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome
29. Exploring the potential cost-effectiveness of precision medicine treatment strategies for diffuse large B-cell lymphoma
30. Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility
31. A phase 2 trial of alisertib in patients with relapsed or refractory B-cellnon-Hodgkin lymphoma
32. Patterns of use and survival outcomes of positron emission tomography for initial staging in elderly follicular lymphoma patients
33. Vaccine Strategies for the Treatment of Lymphoma: Preclinical Progress and Clinical Trial Update
34. [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice
35. B cells gone rogue: the intersection of diffuse large B cell lymphoma and autoimmune disease
36. Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome
37. Population-specific prognostic models are needed to stratify outcomes for African-Americans with diffuse large B-cell lymphoma
38. New insights into the epidemiology of non-Hodgkin lymphoma and implications for therapy
39. Rebirth of radiotherapy for elderly patients with diffuse large B-cell lymphoma in the rituximab era
40. Comparison of the effectiveness of frontline chemoimmunotherapy regimens for follicular lymphoma used in the United States
41. Intensive chemotherapy and consolidation with high dose therapy and autologous stem cell transplant in patients with mantle cell lymphoma
42. The role of chemotherapy in managing chronic lymphocytic leukemia: optimizing combinations with targeted therapy
43. Incidence and survival patterns of cutaneous T-cell lymphomas in the United States
44. Examining racial differences in diffuse large B-cell lymphoma presentation and survival
45. Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma
46. Patterns of Social Support Among Lymphoma Patients Considering Stem Cell Transplantation
47. Idiotype vaccine strategies for improving outcomes in follicular lymphoma
48. Incidence and outcomes of the peripheral T-cell lymphoma subtypes in the United States
49. BiovaxID™ idiotype vaccination: active immunotherapy for follicular lymphoma
50. Practical approach for using Medicare data to estimate costs for cost–effectiveness analysis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.